Advanced search
1 file | 1.39 MB Add to list

Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe

Author
Organization
Abstract
Whole genome/exome sequencing (WGS/WES) has become widely adopted in research and, more recently, in clinical settings. Many hope that the information obtained from the interpretation of these data will have medical benefits for patients and—in some cases—also their biological relatives. Because of the manifold possibilities to reuse genomic data, enabling sequenced individuals to access their own raw (uninterpreted) genomic data is a highly debated issue. This paper reports some of the first empirical findings on personal genome access policies and practices. We interviewed 39 respondents, working at 33 institutions in 21 countries across Europe. These sequencing institutions generate massive amounts of WGS/WES data and represent varying organisational structures and operational models. Taken together, in total, these institutions have sequenced ∼317,259 genomes and exomes to date. Most of the sequencing institutions reported that they are able to store raw genomic data in compliance with various national regulations, although there was a lack of standardisation of storage formats. Interviewees from 12 of the 33 institutions included in our study reported that they had received requests for personal access to raw genomic data from sequenced individuals. In the absence of policies on how to process such requests, these were decided on an ad hoc basis; in the end, at least 28 requests were granted, while there were no reports of requests being rejected. Given the rights, interests, and liabilities at stake, it is essential that sequencing institutions adopt clear policies and processes for raw genomic data retention and personal access.
Keywords
Genetics(clinical), Molecular Medicine, Genetics

Downloads

  • 8661055.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.39 MB

Citation

Please use this url to cite or link to this publication:

MLA
Narayanasamy, Shaman, et al. “Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe.” Frontiers in Genetics, FRONTIERS MEDIA SA, 2020.
APA
Narayanasamy, S., Markina, V., Thorogood, A., Blazkova, A., Shabani, M., Knoppers, B. M., … Koesters, R. (2020). Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe. Frontiers in Genetics.
Chicago author-date
Narayanasamy, Shaman, Varvara Markina, Adrian Thorogood, Adriana Blazkova, Mahsa Shabani, Bartha M. Knoppers, Barbara Prainsack, and Robert Koesters. 2020. “Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe.” Frontiers in Genetics.
Chicago author-date (all authors)
Narayanasamy, Shaman, Varvara Markina, Adrian Thorogood, Adriana Blazkova, Mahsa Shabani, Bartha M. Knoppers, Barbara Prainsack, and Robert Koesters. 2020. “Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe.” Frontiers in Genetics.
Vancouver
1.
Narayanasamy S, Markina V, Thorogood A, Blazkova A, Shabani M, Knoppers BM, et al. Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe. Frontiers in Genetics. 2020;
IEEE
[1]
S. Narayanasamy et al., “Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe,” Frontiers in Genetics, 2020.
@article{8661533,
  abstract     = {Whole genome/exome sequencing (WGS/WES) has become widely adopted in research and, more recently, in clinical settings. Many hope that the information obtained from the interpretation of these data will have medical benefits for patients and—in some cases—also their biological relatives. Because of the manifold possibilities to reuse genomic data, enabling sequenced individuals to access their own raw (uninterpreted) genomic data is a highly debated issue. This paper reports some of the first empirical findings on personal genome access policies and practices. We interviewed 39 respondents, working at 33 institutions in 21 countries across Europe. These sequencing institutions generate massive amounts of WGS/WES data and represent varying organisational structures and operational models. Taken together, in total, these institutions have sequenced ∼317,259 genomes and exomes to date. Most of the sequencing institutions reported that they are able to store raw genomic data in compliance with various national regulations, although there was a lack of standardisation of storage formats. Interviewees from 12 of the 33 institutions included in our study reported that they had received requests for personal access to raw genomic data from sequenced individuals. In the absence of policies on how to process such requests, these were decided on an ad hoc basis; in the end, at least 28 requests were granted, while there were no reports of requests being rejected. Given the rights, interests, and liabilities at stake, it is essential that sequencing institutions adopt clear policies and processes for raw genomic data retention and personal access.},
  author       = {Narayanasamy, Shaman and Markina, Varvara and Thorogood, Adrian and Blazkova, Adriana and Shabani, Mahsa and Knoppers, Bartha M. and Prainsack, Barbara and Koesters, Robert},
  issn         = {1664-8021},
  journal      = {Frontiers in Genetics},
  keywords     = {Genetics(clinical),Molecular Medicine,Genetics},
  language     = {eng},
  publisher    = {FRONTIERS MEDIA SA},
  title        = {Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe},
  url          = {http://dx.doi.org/10.3389/fgene.2020.00303},
  year         = {2020},
}

Altmetric
View in Altmetric